Last reviewed · How we verify
Docetaxel + High dose Vitamin D2
Docetaxel stabilizes microtubules to inhibit cancer cell division, while high-dose vitamin D2 may enhance immune response and potentially sensitize cancer cells to chemotherapy.
Docetaxel stabilizes microtubules to inhibit cancer cell division, while high-dose vitamin D2 may enhance immune response and potentially sensitize cancer cells to chemotherapy. Used for Metastatic or locally advanced solid tumors (under investigation with vitamin D2 co-treatment).
At a glance
| Generic name | Docetaxel + High dose Vitamin D2 |
|---|---|
| Sponsor | King Faisal Specialist Hospital & Research Center |
| Drug class | Taxane chemotherapy + vitamin D supplement combination |
| Target | β-tubulin (docetaxel); vitamin D receptor (VDR) for vitamin D2 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Docetaxel is a taxane that binds to β-tubulin and prevents microtubule depolymerization, leading to cell cycle arrest and apoptosis in rapidly dividing cancer cells. High-dose vitamin D2 supplementation may modulate immune function and enhance the anti-tumor effects of chemotherapy through vitamin D receptor signaling and potential immunomodulatory mechanisms.
Approved indications
- Metastatic or locally advanced solid tumors (under investigation with vitamin D2 co-treatment)
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Peripheral neuropathy
- Hypersensitivity reactions
- Nausea and vomiting
- Fatigue
- Hypercalcemia (from high-dose vitamin D2)
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: